FDx Advisors’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $840K | Buy |
5,362
+1,206
| +29% | +$181K | 0.25% | 68 |
|
|
2026
Q1 | $635K | Buy |
+4,156
| New | +$637K | 0.2% | 81 |
|
|
2024
Q2 | – | Sell |
-4,694
| Closed | -$454K | – | 300 |
|
|
2024
Q1 | $454K | Sell |
4,694
-11,675
| -71% | -$1.2M | 0.07% | 214 |
|
|
2023
Q4 | $1.65M | Buy |
16,369
+651
| +4% | +$62.8K | 0.13% | 166 |
|
|
2023
Q3 | $1.6M | Sell |
15,718
-13,946
| -47% | -$1.42M | 0.13% | 149 |
|
|
2023
Q2 | $2.99M | Sell |
29,664
-28,123
| -49% | -$2.81M | 0.16% | 147 |
|
|
2023
Q1 | $5.24M | Hold |
57,787
| – | – | 0.23% | 106 |
|
|
2022
Q4 | $5.24M | Sell |
57,787
-936
| -2% | -$78.8K | 0.23% | 106 |
|
|
2022
Q3 | $4.46M | Sell |
58,723
-5,878
| -9% | -$487K | 0.2% | 114 |
|
|
2022
Q2 | $5.46M | Buy |
64,601
+1,784
| +3% | +$157K | 0.21% | 106 |
|
|
2022
Q1 | $5.51M | Buy |
62,817
+3,847
| +7% | +$333K | 0.19% | 113 |
|
|
2021
Q4 | $5.16M | Buy |
58,970
+11,566
| +24% | +$960K | 0.14% | 124 |
|
|
2021
Q3 | $3.88M | Buy |
47,404
+3,481
| +8% | +$313K | 0.12% | 131 |
|
|
2021
Q2 | $4.01M | Buy |
43,923
+1,529
| +4% | +$136K | 0.13% | 130 |
|
|
2021
Q1 | $3.62M | Sell |
42,394
-4,831
| -10% | -$434K | 0.14% | 129 |
|
|
2020
Q4 | $4.46M | Buy |
47,225
+4,609
| +11% | +$403K | 0.18% | 107 |
|
|
2020
Q3 | $3.71M | Buy |
42,616
+718
| +2% | +$62.2K | 0.17% | 112 |
|
|
2020
Q2 | $3.66M | Buy |
41,898
+2,895
| +7% | +$250K | 0.19% | 107 |
|
|
2020
Q1 | $3.22M | Buy |
39,003
+5,139
| +15% | +$459K | 0.21% | 96 |
|
|
2019
Q4 | $3.21M | Buy |
33,864
+5,151
| +18% | +$462K | 0.18% | 115 |
|
|
2019
Q3 | $2.5M | Sell |
28,713
-21,544
| -43% | -$1.93M | 0.17% | 112 |
|
|
2019
Q2 | $4.59M | Buy |
50,257
+4,426
| +10% | +$375K | 0.18% | 110 |
|
|
2019
Q1 | $3.95M | Buy |
45,831
+17,414
| +61% | +$1.4M | 0.16% | 113 |
|
|
2018
Q4 | $2.19M | Sell |
28,417
-23,235
| -45% | -$1.81M | 0.18% | 97 |
|
|
2018
Q3 | $3.99M | Buy |
51,652
+980
| +2% | +$72.4K | 0.15% | 108 |
|
|
2018
Q2 | $3.43M | Sell |
50,672
-2,902
| -5% | -$200K | 0.12% | 126 |
|
|
2018
Q1 | $3.88M | Buy |
53,574
+3,011
| +6% | +$229K | 0.12% | 141 |
|
|
2017
Q4 | $3.8M | Buy |
50,563
+7,851
| +18% | +$592K | 0.1% | 161 |
|
|
2017
Q3 | $3.29M | Buy |
42,712
+6,179
| +17% | +$467K | 0.09% | 187 |
|
|
2017
Q2 | $2.73M | Sell |
36,533
-36,642
| -50% | -$2.6M | 0.08% | 214 |
|
|
2017
Q1 | $4.87M | Buy |
73,175
+1,778
| +2% | +$118K | 0.15% | 123 |
|
|
2016
Q4 | $4.66M | Buy |
71,397
+35,477
| +99% | +$2.3M | 0.13% | 138 |
|
|
2016
Q3 | $2.54M | Buy |
35,920
+426
| +1% | +$31K | 0.11% | 155 |
|
|
2016
Q2 | $2.62M | Sell |
35,494
-5,339
| -13% | -$369K | 0.12% | 152 |
|
|
2016
Q1 | $2.65M | Buy |
40,833
+4,567
| +13% | +$311K | 0.12% | 145 |
|
|
2015
Q4 | $2.8M | Buy |
36,266
+3,986
| +12% | +$317K | 0.13% | 136 |
|
|
2015
Q3 | $2.66M | Sell |
32,280
-3,443
| -10% | -$306K | 0.23% | 83 |
|
|
2015
Q2 | $3.13M | Buy |
35,723
+2,801
| +9% | +$257K | 0.16% | 115 |
|
|
2015
Q1 | $2.91M | Sell |
32,922
-15,281
| -32% | -$1.36M | 0.06% | 228 |
|
|
2014
Q4 | $4M | Sell |
48,203
-1,644
| -3% | -$136K | 0.24% | 71 |
|
|
2014
Q3 | $4.2M | Sell |
49,847
-15,730
| -24% | -$1.27M | 0.27% | 63 |
|
|
2014
Q2 | $5.32M | Buy |
65,577
+14,184
| +28% | +$1.12M | 0.35% | 45 |
|
|
2014
Q1 | $3.92M | Sell |
51,393
-6,885
| -12% | -$502K | 0.33% | 53 |
|
|
2013
Q4 | $4.19M | Sell |
58,278
-13,599
| -19% | -$945K | 0.42% | 35 |
|
|
2013
Q3 | $4.94M | Sell |
71,877
-914
| -1% | -$60.5K | 0.58% | 19 |
|
|
2013
Q2 | $4.61M | Buy |
+72,791
| New | +$4.74M | 0.61% | 18 |
|
Other funds holding NVS
FDx Advisors's NVS Position: Q2 2026 in Review
FDx Advisors increased its Novartis (NVS) stake by 29% in Q2 2026, buying an estimated $181K and bringing the position to 5,362 shares worth $840K. The position accounts for 0.25% of the portfolio, ranked #68.
FDx Advisors first reported a position in NVS in Q2 2013 and has held it in 46 quarters since. The position peaked at $5.51M in Q1 2022. 1,617 funds tracked by Wall St. Rank hold NVS as of Q2 2026.
- FDx Advisors held 5,362 shares of Novartis worth $840K as of Q2 2026.
- FDx Advisors bought 1,206 Novartis shares in Q2 2026, an estimated $181K.
- Novartis made up 0.25% of FDx Advisors's portfolio in Q2 2026, its #68 holding.
- FDx Advisors first reported a position in Novartis in Q2 2013 and has held it in 46 quarters since.
- FDx Advisors's Novartis position peaked at $5.51M in Q1 2022.
- 1,617 funds tracked by Wall St. Rank held Novartis as of Q2 2026.
Based on FDx Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.